Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
Immunotherapy Combined With Chemoradiotherapy Shows Promise for Lung Cancer
This meta-analysis of randomized controlled trials evaluated the impact of chemoradiotherapy (CCRT) plus immunotherapy on 1,853 patients wit…
Adding immunotherapy to standard chemoradiotherapy shows a favorable trend in survival for patients with limited-stage small-cell lung cance…
Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer
Nab-paclitaxel shows similar results to paclitaxel for lung cancer
This meta-analysis examined paclitaxel monotherapy in relapsed small cell lung cancer. The 3-month progression-free survival rate was modest…
New data compares two types of paclitaxel treatments for relapsed small cell lung cancer, showing similar safety and effectiveness.
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
Immune drugs boost survival in small-cell lung cancer
This systematic review and meta-analysis evaluates immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for ext…
Adding immune checkpoint inhibitors to chemotherapy helps patients with extensive-stage small-cell lung cancer live longer.
Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
Doctors are still figuring out the best way to treat extensive-stage small cell lung cancer
This review examines the use of thoracic radiotherapy combined with chemoimmunotherapy in patients with extensive-stage small cell lung canc…
A review notes that while combining radiation with chemotherapy and immune therapy helps some patients, the best approach is still being stu…
Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
Lung Scans Get Smarter With New Imaging Tool
This narrative review examines the utility of 68Ga-Pentixafor PET/CT in patients with lung cancer.
You wake up, cough again — just like the past few weeks.
Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
New Drug Combo Fails to Shrink Tough Lung and Bladder Cancers
This cohort study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer, small cell lung cancer, and ur…
This study shows that adding a new drug to standard chemotherapy did not help patients with advanced lung or bladder cancer live longer or s…
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
Combined Treatments May Help Manage Brain Metastases in Lung Cancer
This case report and literature review describes a patient with EGFR-mutant NSCLC and brain/leptomeningeal metastases. The authors suggest t…
A new treatment approach combining surgery, local chemotherapy, and targeted drugs may help manage brain cancer spread for some patients.
Lower baseline soluble PD-L1 levels correlate with improved progression-free and overall survival in NSCLC
Blood Marker May Predict Lung Cancer Outcomes
This meta-analysis of 1967 patients with non-small cell lung cancer (NSCLC) found that lower baseline sPD-L1 levels are associated with sign…
A protein in the blood called sPD-L1 may help predict how well lung cancer patients respond to treatment.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
New Guidelines Redefine Surgery Options for Lung Cancer Patients
This clinical guideline addresses the management of stage III non-small cell lung cancer (NSCLC). It advocates for a multidisciplinary appro…
New guidelines suggest that surgery for certain lung cancers should be based on tumor biology and treatment response rather than just anatom…
Ensartinib improves 24-month disease-free survival to 86.4% in resected ALK-positive NSCLC
New drug shows promise for specific type of lung cancer
This Phase 3 randomized trial of 274 patients with resected, ALK-positive stage IB to IIIB NSCLC found that ensartinib (225 mg once daily) s…
A new medication called ensartinib significantly improved the time patients lived without their lung cancer returning after surgery.
Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
Lung cancer can change form after targeted drug treatment
A case report with literature review describes a 71-year-old man with KRAS G12C-mutant lung adenocarcinoma whose tumor transformed to pulmon…
A man's lung cancer transformed into a more aggressive type after taking the targeted drug sotorasib, highlighting the need for re-biopsy wh…
PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
Adding PD-1 inhibitors to chemotherapy improves lung cancer survival
This network meta-analysis of 20 randomized controlled trials evaluated treatments for driver gene-negative non-small cell lung cancer with …
Combining a specific immunotherapy drug with chemotherapy may help patients with certain types of lung cancer and liver spread live longer.
TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
Antibody-drug conjugates show promise for lung cancer after TKI failure
This systematic review and meta-analysis of 1092 patients found that antibody-drug conjugates (ADCs) provide significant clinical benefits f…
New research highlights how specific antibody-drug conjugates may offer better outcomes for patients with certain types of lung cancer.
Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
Understanding why some lung cancer treatments do not work for every patient
This systematic review synthesizes mechanisms of primary and acquired resistance to PD-1/PD-L1 inhibitors in patients with non-small cell lu…
Doctors are studying why certain immune-boosting drugs fail to stop lung cancer growth. New insights help find better ways to treat patients…
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Single-cell and spatial omics provide detailed mapping of tumor-immune ecosystems in non-small cell lung cancer
New Mapping Tools May Improve Lung Cancer Treatment Planning
This mini review explores how single-cell RNA sequencing, chromatin profiling, and spatial transcriptomics offer superior resolution for ana…
Advanced mapping techniques are helping researchers identify how lung cancer cells adapt and hide from current treatments to help plan bette…
CT-based deep learning models show high accuracy predicting EGFR mutation status in lung adenocarcinoma
Machine learning models help predict lung cancer mutations from scans
This meta-analysis of 6,628 Chinese patients with lung adenocarcinoma found that machine learning-based radiomics models provide a noninvasi…
New analysis shows that deep learning models can accurately identify specific lung cancer mutations using standard CT scans.
Questions about Small Cell Lung Cancer
Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?
Yes, a phase II trial found toripalimab plus anlotinib maintenance after first-line chemo led to median progression-free survival of 8.18 months and overall survival of 23.05 months in ES-SCLC.
Full answer →Do bispecific antibodies or CAR T-cell therapy treat advanced Small Cell Lung Cancer?
Yes, both bispecific antibodies and CAR T-cell therapy are being studied for advanced SCLC, with bispecific antibodies showing more clinical progress, especially tarlatamab targeting DLL3.
Full answer →Do immune checkpoint inhibitors improve survival for first-line Small Cell Lung Cancer treatment?
Yes, immune checkpoint inhibitors combined with chemotherapy improve survival as first-line treatment for extensive-stage small-cell lung cancer.
Full answer →All Small Cell Lung Cancer Articles
- Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
- Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer
- Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
- Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
- Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
- Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
- Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
- Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
- Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
- Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
- Narrative review summarizes bispecific antibodies and CAR T-cell therapy for advanced lung cancer
- In a phase 2 trial, [Ga]Ga-SSO120 PET/CT detected malignancies in 18 of 19 patients with small cell or large cell neuroendocrine lung cancer
- Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
- Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC